Preclinical
Nearly 50 infants with “bubble baby” disease developed a working immune system after they received a gene therapy that contained the AIDS virus, according to a new study.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
BioSpace takes a look at data released this week from some of the numerous ongoing clinical studies to advance potential therapies and treatment for disease. Here are some of them.
Patients without diabetes who develop COVID-19 may be at a higher risk of actually developing diabetes following recovery, recent study claims.
PRESS RELEASES